Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.10    0.00 (0.00%)
Bid:
1.00
Ask:
1.10
Spread: 0.10 (10.00%)
Market Cap: £25.80m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

AGM Statement

30 Sep 2013 07:00

RNS Number : 1267P
Provexis PLC
30 September 2013
 



30 September 2013

 

Provexis plc

 

AGM Statement

 

Provexis plc ("Provexis" or the "Company"), the business that develops and licenses scientifically-proven functional food, will hold its Annual General Meeting in Reading later today.

 

At the meeting Dawson Buck, the non-executive Chairman of the Company, will give the following update on developments:

 

"The Company has undergone major change during the last year, with the Science in Sport business being demerged from Provexis and the cost base of the legacy Provexis business being significantly reduced. The demerger resulted in a substantial increase in shareholder value.

 

DSM Nutritional Products continues to develop the market actively for our novel, patented Fruitflow® heart-health ingredient in all global markets. Currently, over 20 regional consumer healthcare and dietary supplement brands containing the ingredient are now in the market. The heart-healthy dietary supplement segment is highly competitive and in some markets highly regulated, which requires country by country analysis and marketing strategy development and thus time to gain adoption and achieve success.

 

Much focus has been given to the development of a concentrated, powder version of Fruitflow®, suitable for tablets, gel capsules and other dietary supplements. While manufacturing set up costs of a supply chain to produce this powder will adversely affect cost of goods in the year, this format is regarded as being the required format for brand owners and as such, this investment by DSM is seen as important to the future growth of Fruitflow® revenues in the important dietary supplements sector.

 

Costs in Provexis have been reduced drastically, and together with a recent drawdown of funds, the company has sufficient cash to fund operations until early 2016.

 

With this very focused model and low operating costs, the directors believe the Company is in a strong position."

 

 

-ends-

 

For further information please contact:

 

Stephen Moon, Chief Executive

Provexis plc Tel: 01753 861777

 

Bobbie Hilliam Tel: 020 7397 8900

Cenkos Securities plc

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMFDLFLXKFEBBL
Date   Source Headline
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options
10th Sep 20197:00 amRNSFinal Results
2nd Aug 20197:00 amRNSCollaboration agreement with By-Health Co., Ltd.
31st Jul 20197:00 amRNSTrading Update
27th Jun 20193:11 pmRNSTiming of trading update
12th Apr 20197:00 amRNSBoard changes
8th Mar 20199:44 amRNSHolding(s) in Company
31st Dec 20187:00 amRNSHalf-year Report
1st Nov 20181:00 pmRNSChange of Adviser and AIM Rule 17 notice
25th Oct 20181:55 pmRNSResult of AGM
16th Oct 20187:00 amRNSHolding(s) in Company
9th Oct 20184:25 pmRNSHolding(s) in Company
27th Sep 20187:10 amRNSFinal Results
27th Sep 20187:00 amRNSResults of Placing
4th Jul 20187:00 amRNSDirectorate Change - Frédéric Boned
25th Jun 20187:00 amRNSFruitflow®+ Omega-3 launch in Holland & Barrett
5th Feb 20182:16 pmRNSHolding(s) in Company
31st Jan 20188:21 amRNSDirectorate Change - Krijn Rietveld
2nd Jan 20187:00 amRNSGrant of Share Options
29th Dec 20177:09 amRNSHalf-year Report
4th Dec 20177:00 amRNSPatent application - Fruitflow and air pollution
10th Nov 20174:40 pmRNSSecond Price Monitoring Extn
10th Nov 20174:35 pmRNSPrice Monitoring Extension
2nd Nov 20174:41 pmRNSSecond Price Monitoring Extn
2nd Nov 20174:35 pmRNSPrice Monitoring Extension
31st Oct 20174:40 pmRNSSecond Price Monitoring Extn
31st Oct 20174:35 pmRNSPrice Monitoring Extension
3rd Oct 20174:10 pmRNSResult of AGM
26th Sep 20172:44 pmRNSStudy Publication
7th Sep 20177:00 amRNSPreliminary Results
4th Aug 20178:00 amRNSHolding(s) in Company
31st Jul 20177:59 amRNSResults of placing
28th Jul 20174:30 pmRNSFunding Update
3rd Jul 20177:00 amRNSFunding Update
9th Jun 20174:35 pmRNSPrice Monitoring Extension
5th Jun 20174:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.